
    
      This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the
      safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple
      doses of MEDI3506 administered by either subcutaneous (SC) or intravenous (IV) routes.

      Part I: Single Ascending Doses in Healthy Participants with a History of Mild Atopy

      Part II: Multiple Ascending Doses in Participants with Global Initiative for Chronic
      Obstructive Lung Disease (GOLD) I-II Chronic Obstructive Pulmonary Disease (COPD)

      Part III: Single Dose in Healthy Japanese Participants
    
  